1naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
PT  - JOURNAL ARTICLE
AU  - Wesolowski, J.R.
AU  - Rajdev, P.
AU  - Mukherji, S.K.
TI  - Temozolomide (Temodar)
AID  - 10.3174/ajnr.A2170
DP  - 2010 Sep 01
TA  - American Journal of Neuroradiology
PG  - 1383--1384
VI  - 31
IP  - 8
4099  - http://www.ajnr.org/content/31/8/1383.short
4100  - http://www.ajnr.org/content/31/8/1383.full
SO  - Am. J. Neuroradiol.2010 Sep 01; 31
AB  - SUMMARY: Temozolomide, an oral alkylating agent, is a commonly used medicine in the treatment of anaplastic astrocytoma and glioblastoma multiforme. This paper will present the mechanism of action as well as the clinical role for this chemotherapeutic drug. FDAUS Food and Drug AdministrationMTICmethyl triazeno imidazole carboxamide